# MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study

> **NCT04168385** · PHASE2 · COMPLETED · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Cholestatic Liver Disease

## Interventions

- **DRUG:** Maralixibat

## Key facts

- **NCT ID:** NCT04168385
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-16
- **Primary completion:** 2024-09-04
- **Final completion:** 2024-09-04
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04168385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04168385, "MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04168385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*